{"name":"CSL Behring","slug":"csl-behring","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2023-12-22","label":"Filsuvez first approved","drug":"Filsuvez","drugSlug":"garadacimab","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2029-09-01","label":"Filsuvez Phase 3 readout (Epidermolysis Bullosa, Junctional Epidermolysis Bullosa)","drug":"Filsuvez","drugSlug":"garadacimab","type":"phase3_readout","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":23,"colorKey":"oncology","drugs":[{"name":"CSL112","genericName":"CSL112","slug":"csl112","indication":"Other","status":"phase_2"},{"name":"Filsuvez","genericName":"garadacimab","slug":"garadacimab","indication":"Epidermolysis bullosa","status":"marketed"},{"name":"Hizentra","genericName":"Hizentra","slug":"hizentra","indication":"Other","status":"marketed"},{"name":"IgPro10","genericName":"IgPro10","slug":"igpro10","indication":"Other","status":"marketed"},{"name":"ANDEMBRY","genericName":"GARADACIMAB-GXII","slug":"garadacimab-gxii","indication":"Prophylaxis for HAE","status":"marketed"},{"name":"Afstyla","genericName":"LONOCTOCOG ALFA","slug":"lonoctocog-alfa","indication":"Hereditary factor VIII deficiency disease","status":"marketed"},{"name":"BE1116","genericName":"BE1116","slug":"be1116","indication":"Von Willebrand disease (prophylaxis and treatment of bleeding episodes)","status":"phase_3"},{"name":"Biostate","genericName":"Biostate","slug":"biostate","indication":"Other","status":"discontinued"},{"name":"Biostate® [RP]","genericName":"Biostate® [RP]","slug":"biostate-rp","indication":"Hereditary angioedema","status":"phase_2"},{"name":"Biostate® [SP]","genericName":"Biostate® [SP]","slug":"biostate-sp","indication":"Hereditary angioedema","status":"phase_2"},{"name":"Blood coagulation Factor VIII and vWF, human","genericName":"Blood coagulation Factor VIII and vWF, human","slug":"blood-coagulation-factor-viii-and-vwf-human","indication":"Other","status":"marketed"},{"name":"CE1226","genericName":"CE1226","slug":"ce1226","indication":"Other","status":"marketed"},{"name":"CSL300","genericName":"CSL300","slug":"csl300","indication":"Paroxysmal nocturnal hemoglobinuria (PNH)","status":"phase_2"},{"name":"CSL_112","genericName":"CSL_112","slug":"csl-112","indication":"Paroxysmal nocturnal hemoglobinuria (PNH)","status":"phase_2"},{"name":"Cryoprecipitate","genericName":"Cryoprecipitate","slug":"cryoprecipitate","indication":"Other","status":"marketed"},{"name":"FXIII Concentrate (Human)","genericName":"FXIII Concentrate (Human)","slug":"fxiii-concentrate-human","indication":"Congenital Factor XIII deficiency (FXIII deficiency)","status":"phase_3"},{"name":"Higher-volume C1-esterase inhibitor","genericName":"Higher-volume C1-esterase inhibitor","slug":"higher-volume-c1-esterase-inhibitor","indication":"Hereditary angioedema (HAE) with C1-INH deficiency or dysfunction","status":"phase_3"},{"name":"Idelvion","genericName":"ALBUTREPENONACOG ALFA","slug":"albutrepenonacog-alfa","indication":"Hereditary factor IX deficiency disease","status":"marketed"},{"name":"Low-volume C1-esterase inhibitor","genericName":"Low-volume C1-esterase inhibitor","slug":"low-volume-c1-esterase-inhibitor","indication":"Hereditary angioedema (HAE) with C1-INH deficiency or dysfunction","status":"phase_3"},{"name":"Vamifeport PR1","genericName":"Vamifeport PR1","slug":"vamifeport-pr1","indication":"Other","status":"phase_1"},{"name":"Vivaglobin","genericName":"Vivaglobin","slug":"vivaglobin","indication":"Other","status":"marketed"},{"name":"Voncento","genericName":"Voncento","slug":"voncento","indication":"Other","status":"marketed"},{"name":"rVIIa-FP","genericName":"rVIIa-FP","slug":"rviia-fp","indication":"Other","status":"phase_1"}]},{"name":"Rare Disease","slug":"rare-disease","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"immunology","drugs":[{"name":"Afstyla®","genericName":"Afstyla®","slug":"afstyla","indication":"Hemophilia A (congenital factor VIII deficiency) for routine prophylaxis and treatment of bleeding episodes","status":"marketed"},{"name":"Factor IX (FIX)","genericName":"Factor IX (FIX)","slug":"factor-ix-fix","indication":"Hemophilia B (Factor IX deficiency) — prevention and treatment of bleeding episodes","status":"phase_3"},{"name":"rIX-FP","genericName":"rIX-FP","slug":"rix-fp","indication":"Prevention of bleeding in patients with hemophilia A","status":"phase_3"},{"name":"rVIII-SingleChain","genericName":"rVIII-SingleChain","slug":"rviii-singlechain","indication":"Hemophilia A (treatment and prophylaxis of bleeding episodes)","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"respiratory","drugs":[{"name":"IgPro","genericName":"IgPro","slug":"igpro","indication":"Primary immunodeficiency disorders","status":"marketed"},{"name":"IgPro20","genericName":"IgPro20","slug":"igpro20","indication":"Primary immunodeficiency disorders requiring immunoglobulin replacement therapy","status":"marketed"},{"name":"IgPro20 (high dose)","genericName":"IgPro20 (high dose)","slug":"igpro20-high-dose","indication":"Primary immunodeficiency disorders requiring immunoglobulin replacement therapy","status":"phase_3"},{"name":"IgPro20 (low dose)","genericName":"IgPro20 (low dose)","slug":"igpro20-low-dose","indication":"Primary immunodeficiency disorders requiring immunoglobulin replacement therapy","status":"phase_3"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"neuroscience","drugs":[{"name":"Beriplex® P/N (Kcentra)","genericName":"Beriplex® P/N (Kcentra)","slug":"beriplex-p-n-kcentra","indication":"Urgent reversal of warfarin anticoagulation in patients with life-threatening bleeding","status":"phase_3"},{"name":"CSL312","genericName":"CSL312","slug":"csl312","indication":"Acute coronary syndrome with elevated lipoprotein(a)","status":"phase_3"},{"name":"Haemocomplettan® P","genericName":"Haemocomplettan® P","slug":"haemocomplettan-p","indication":"Reversal of vitamin K antagonist (warfarin) anticoagulation in acute bleeding or urgent procedures","status":"marketed"}]},{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Alpha-1 antitrypsin (AAT)","genericName":"Alpha-1 antitrypsin (AAT)","slug":"alpha-1-antitrypsin-aat","indication":"Alpha-1 antitrypsin deficiency with emphysema","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"infectious","drugs":[{"name":"CSL346","genericName":"CSL346","slug":"csl346","indication":"Relapsed or refractory B-cell non-Hodgkin lymphoma","status":"phase_2"}]}],"pipeline":[{"name":"CSL112","genericName":"CSL112","slug":"csl112","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Filsuvez","genericName":"garadacimab","slug":"garadacimab","phase":"marketed","mechanism":"Monoclonal antibody that inhibits activated Factor XII (FXIIa), preventing the generation of bradykinin which causes angioedema attacks.","indications":["Epidermolysis bullosa"],"catalyst":""},{"name":"Hizentra","genericName":"Hizentra","slug":"hizentra","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"IgPro10","genericName":"IgPro10","slug":"igpro10","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"ANDEMBRY","genericName":"GARADACIMAB-GXII","slug":"garadacimab-gxii","phase":"marketed","mechanism":"Garadacimab-gxii inhibits activated FXII, reducing the activation of prekallikrein and bradykinin generation, thereby decreasing inflammation and swelling in HAE attacks.","indications":["Prophylaxis for HAE"],"catalyst":""},{"name":"Afstyla","genericName":"LONOCTOCOG ALFA","slug":"lonoctocog-alfa","phase":"marketed","mechanism":"Recombinant protein","indications":["Hereditary factor VIII deficiency disease"],"catalyst":""},{"name":"Afstyla®","genericName":"Afstyla®","slug":"afstyla","phase":"marketed","mechanism":"Afstyla is a recombinant antithrombin III-free factor VIII that replaces deficient clotting factor VIII to restore hemostasis in patients with hemophilia A.","indications":["Hemophilia A (congenital factor VIII deficiency) for routine prophylaxis and treatment of bleeding episodes"],"catalyst":""},{"name":"Alpha-1 antitrypsin (AAT)","genericName":"Alpha-1 antitrypsin (AAT)","slug":"alpha-1-antitrypsin-aat","phase":"phase_3","mechanism":"Alpha-1 antitrypsin (AAT) is a protease inhibitor that replaces deficient endogenous AAT to prevent neutrophil elastase-mediated tissue destruction in the lungs and other organs.","indications":["Alpha-1 antitrypsin deficiency with emphysema","Alpha-1 antitrypsin deficiency with progressive lung disease","Alpha-1 antitrypsin deficiency-related liver disease"],"catalyst":""},{"name":"BE1116","genericName":"BE1116","slug":"be1116","phase":"phase_3","mechanism":"BE1116 is a recombinant human albumin-von Willebrand factor (VWF) fusion protein that replaces or augments deficient VWF function in von Willebrand disease.","indications":["Von Willebrand disease (prophylaxis and treatment of bleeding episodes)"],"catalyst":""},{"name":"Beriplex® P/N (Kcentra)","genericName":"Beriplex® P/N (Kcentra)","slug":"beriplex-p-n-kcentra","phase":"phase_3","mechanism":"Beriplex P/N is a prothrombin complex concentrate that replaces deficient vitamin K-dependent clotting factors to rapidly reverse warfarin anticoagulation.","indications":["Urgent reversal of warfarin anticoagulation in patients with life-threatening bleeding","Reversal of warfarin anticoagulation in patients requiring emergency surgery or urgent procedures"],"catalyst":""},{"name":"Biostate","genericName":"Biostate","slug":"biostate","phase":"discontinued","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Biostate® [RP]","genericName":"Biostate® [RP]","slug":"biostate-rp","phase":"phase_2","mechanism":"Biostate is a recombinant human C1 esterase inhibitor used to treat hereditary angioedema.","indications":["Hereditary angioedema"],"catalyst":""},{"name":"Biostate® [SP]","genericName":"Biostate® [SP]","slug":"biostate-sp","phase":"phase_2","mechanism":"Biostate is a recombinant human C1 esterase inhibitor used to treat hereditary angioedema.","indications":["Hereditary angioedema"],"catalyst":""},{"name":"Blood coagulation Factor VIII and vWF, human","genericName":"Blood coagulation Factor VIII and vWF, human","slug":"blood-coagulation-factor-viii-and-vwf-human","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CE1226","genericName":"CE1226","slug":"ce1226","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"CSL300","genericName":"CSL300","slug":"csl300","phase":"phase_2","mechanism":"CSL300 is a recombinant human monoclonal antibody that targets the complement system.","indications":["Paroxysmal nocturnal hemoglobinuria (PNH)"],"catalyst":""},{"name":"CSL312","genericName":"CSL312","slug":"csl312","phase":"phase_3","mechanism":"CSL312 is an apolipoprotein A-I (apoA-I) mimetic that increases HDL cholesterol and promotes reverse cholesterol transport.","indications":["Acute coronary syndrome with elevated lipoprotein(a)","Cardiovascular risk reduction in patients with low HDL cholesterol"],"catalyst":""},{"name":"CSL346","genericName":"CSL346","slug":"csl346","phase":"phase_2","mechanism":"CSL346 is a monoclonal antibody targeting the CD19 protein.","indications":["Relapsed or refractory B-cell non-Hodgkin lymphoma"],"catalyst":""},{"name":"CSL_112","genericName":"CSL_112","slug":"csl-112","phase":"phase_2","mechanism":"CSL_112 is a recombinant human monoclonal antibody that targets the complement system.","indications":["Paroxysmal nocturnal hemoglobinuria (PNH)"],"catalyst":""},{"name":"Cryoprecipitate","genericName":"Cryoprecipitate","slug":"cryoprecipitate","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"FXIII Concentrate (Human)","genericName":"FXIII Concentrate (Human)","slug":"fxiii-concentrate-human","phase":"phase_3","mechanism":"FXIII Concentrate replaces deficient coagulation Factor XIII to restore normal blood clot cross-linking and stabilization.","indications":["Congenital Factor XIII deficiency (FXIII deficiency)","Perioperative prophylaxis in Factor XIII-deficient patients"],"catalyst":""},{"name":"Factor IX (FIX)","genericName":"Factor IX (FIX)","slug":"factor-ix-fix","phase":"phase_3","mechanism":"Factor IX is a vitamin K-dependent clotting factor that replaces deficient or dysfunctional Factor IX to restore the intrinsic coagulation pathway and enable normal blood clot formation.","indications":["Hemophilia B (Factor IX deficiency) — prevention and treatment of bleeding episodes","Hemophilia B — perioperative management"],"catalyst":""},{"name":"Haemocomplettan® P","genericName":"Haemocomplettan® P","slug":"haemocomplettan-p","phase":"marketed","mechanism":"Haemocomplettan® P is a prothrombin complex concentrate (PCC) that replaces deficient vitamin K-dependent clotting factors to restore coagulation capacity.","indications":["Reversal of vitamin K antagonist (warfarin) anticoagulation in acute bleeding or urgent procedures","Treatment of coagulopathy due to liver disease or factor deficiency"],"catalyst":""},{"name":"Higher-volume C1-esterase inhibitor","genericName":"Higher-volume C1-esterase inhibitor","slug":"higher-volume-c1-esterase-inhibitor","phase":"phase_3","mechanism":"A higher-concentration formulation of C1-esterase inhibitor that suppresses activation of the contact system and complement cascade to prevent angioedema attacks.","indications":["Hereditary angioedema (HAE) with C1-INH deficiency or dysfunction","Acute angioedema attacks in HAE patients"],"catalyst":""},{"name":"Idelvion","genericName":"ALBUTREPENONACOG ALFA","slug":"albutrepenonacog-alfa","phase":"marketed","mechanism":"Recombinant protein","indications":["Hereditary factor IX deficiency disease"],"catalyst":""},{"name":"IgPro","genericName":"IgPro","slug":"igpro","phase":"marketed","mechanism":"IgPro is an intravenous immunoglobulin (IVIG) product that provides passive immunity by supplying pooled human antibodies to help fight infections and modulate immune responses.","indications":["Primary immunodeficiency disorders","Secondary immunodeficiency in hematologic malignancies","Chronic inflammatory demyelinating polyneuropathy (CIDP)","Multifocal motor neuropathy","Immune thrombocytopenia (ITP)"],"catalyst":""},{"name":"IgPro20","genericName":"IgPro20","slug":"igpro20","phase":"marketed","mechanism":"IgPro20 is a subcutaneous immunoglobulin replacement therapy that provides passive immunity by delivering polyclonal human immunoglobulins to patients with primary immunodeficiency.","indications":["Primary immunodeficiency disorders requiring immunoglobulin replacement therapy","Secondary immunodeficiency in patients with recurrent infections"],"catalyst":""},{"name":"IgPro20 (high dose)","genericName":"IgPro20 (high dose)","slug":"igpro20-high-dose","phase":"phase_3","mechanism":"IgPro20 is a subcutaneous immunoglobulin replacement therapy that provides passive immunity by delivering polyclonal human immunoglobulins to treat primary immunodeficiency.","indications":["Primary immunodeficiency disorders requiring immunoglobulin replacement therapy"],"catalyst":""},{"name":"IgPro20 (low dose)","genericName":"IgPro20 (low dose)","slug":"igpro20-low-dose","phase":"phase_3","mechanism":"IgPro20 is a subcutaneous immunoglobulin replacement therapy that provides passive immunity by delivering polyclonal human immunoglobulins to patients with primary immunodeficiency.","indications":["Primary immunodeficiency disorders requiring immunoglobulin replacement therapy"],"catalyst":""},{"name":"Low-volume C1-esterase inhibitor","genericName":"Low-volume C1-esterase inhibitor","slug":"low-volume-c1-esterase-inhibitor","phase":"phase_3","mechanism":"Low-volume C1-esterase inhibitor (C1-INH) replaces or augments deficient or dysfunctional C1-esterase inhibitor protein to suppress excessive contact system and complement activation.","indications":["Hereditary angioedema (HAE) with C1-INH deficiency or dysfunction","Acute angioedema attacks in HAE patients"],"catalyst":""},{"name":"Vamifeport PR1","genericName":"Vamifeport PR1","slug":"vamifeport-pr1","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Vivaglobin","genericName":"Vivaglobin","slug":"vivaglobin","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Voncento","genericName":"Voncento","slug":"voncento","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"rIX-FP","genericName":"rIX-FP","slug":"rix-fp","phase":"phase_3","mechanism":"rIX-FP is a recombinant, humanized monoclonal antibody that targets factor VIII to prevent bleeding in patients with hemophilia A.","indications":["Prevention of bleeding in patients with hemophilia A"],"catalyst":""},{"name":"rVIII-SingleChain","genericName":"rVIII-SingleChain","slug":"rviii-singlechain","phase":"phase_3","mechanism":"rVIII-SingleChain is a recombinant single-chain factor VIII that replaces deficient clotting factor VIII to restore hemostasis in hemophilia A patients.","indications":["Hemophilia A (treatment and prophylaxis of bleeding episodes)"],"catalyst":""},{"name":"rVIIa-FP","genericName":"rVIIa-FP","slug":"rviia-fp","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxPb25Md0I4Zi0zTXNwOHZ5aW9lN3JpTll1dGJIeDJFdndKcDh3QlNUZk5Fb2JpRnM3d09Zd0R4TThuNzM2VVhuN09aRGFMNWdCMVZGakFWNGwyTDdLWm1XQUVhZGUtN3o1ekxUVmtuZlM3WHJlbW8xR0RlM2lEVkw2M19UVjF1c2pHSE5nRi1WdTF3c3l3WUZON0dDVUx3aVpJZTdkQXBMTkM5TUoyclpDVmRwWjduN1JiSGdOSHRNYWZYV0VkRTBj?oc=5","date":"2026-03-10","type":"pipeline","source":"Fierce Pharma","summary":"CSL telegraphs 300 new hires as it breaks ground on $1.5B plasma-based medicine plant near Chicago - Fierce Pharma","headline":"CSL telegraphs 300 new hires as it breaks ground on $1.5B plasma-based medicine plant near Chicago","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxNY1hxbks4dHpxUThfeHBmX3czcTk1dXhDYktzSS15STMybzVCSzRHa21UU3prLVhQZVBtZ3UySXpzelEyMGNseEtWMHZxTFlVY0xOUV9sNi1ld3N5X1diNVVfalgxRDJucWRVY1BvS2ZiVDFUc1FZaG9ubURHcFR0eG9lTnBfU0Z4dlZ5WW1oWWNYMWFGTWFPSERFNC0wUHJBamJjQXlR?oc=5","date":"2026-02-16","type":"pipeline","source":"SWI swissinfo.ch","summary":"Pharma company CSL Behring plans Swiss job cuts - SWI swissinfo.ch","headline":"Pharma company CSL Behring plans Swiss job cuts","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE0wR3lJaXVwRHpiUEJldVRkb2hkcWVsWnVuOGxFTWdvSDlDenRmelcyeU1sLUVGSXZyLWxMTjZPUHJDWl9yZl9GeTA1SzRJYTVySDFLU3Q5Yi1VMUN2QjlJ?oc=5","date":"2025-11-22","type":"pipeline","source":"VISTA.Today","summary":"CSL to Invest $1.5B in U.S. Growth Amid Restructuring and Local Layoffs - VISTA.Today","headline":"CSL to Invest $1.5B in U.S. Growth Amid Restructuring and Local Layoffs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxObmFOWFVvNEZxZk1PZ0Z0WFdTR0ZGY1Y1RlI4dEhjRVpHU0VPeEQtb3p6dkNDdXhrT0hTZFVjcnc2NFdnb1l5UE5DVklMUjVwWjVvckZNeU14LXdxdHRuZHVZTEVKT2hKeG9RNFNqUWpXVWN2WTRqNWE2VXJFRTZ6cXBiX2UyanU3N2Y4cTg3N05jeFlHQmdULQ?oc=5","date":"2025-11-19","type":"pipeline","source":"Pharmaceutical Technology","summary":"CSL to pump $1.5bn into US plasma supply chain - Pharmaceutical Technology","headline":"CSL to pump $1.5bn into US plasma supply chain","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxORl9pVDBTQTZuMWlhZFZjR0FuNDN1OElIMlNNNEpfOXJ5dlhkSlJ3eW4wV2xkUS1RTXNKNHZpT240ajFraFpJUlBRQTk3OG5ia3kwck0wODR4SWZaVVNQVmlQOUpwQS1GNktrNnJHRnluWkNhVk5BVHRFLWhhWW1sdG40THdGT0RKbmQ5RVE4X1dqTVVjTTBXcHdoUEZaSHVyd09rdkdKWFVOSHl4Z0hMWS1mWlJOREk?oc=5","date":"2025-11-18","type":"pipeline","source":"The Pharma Letter","summary":"CSL to invest $1.5 billion in USA to manufacture plasma-derived therapies - The Pharma Letter","headline":"CSL to invest $1.5 billion in USA to manufacture plasma-derived therapies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxNQVJQYzNVWEt1aEZTYnQ5c2VZYnoxTnNkUXpnMHFQcWw0RC1lQy1pWnNKUGVRSzJ0TkNrQlBGbk9LdmJCS0FNRnVfWmJQNzZGZjd2V1hpTXhleWRfMXpQc3RUcG1Qd1lmY3Y4RkpLMl9VOTFBSHZBNHV3VzhxVFpJM0NLaGJjYUhVM1RJdFQtNERJaS1uTkN0TjNtbG1UVjlNclFTMA?oc=5","date":"2025-11-18","type":"pipeline","source":"Fierce Pharma","summary":"CSL charts US plasma manufacturing expansion with $1.5B investment - Fierce Pharma","headline":"CSL charts US plasma manufacturing expansion with $1.5B investment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxQcEZiNUE0YlRkMEJzaWxiR2dSbm1wZHVpYlhOWkx4TTJyeUVvVHBURXI5cjZweHMtcDhOWlNmMlkzQ3dyLVNIMVI4RGYtMkE2YW1NMXZqRi1ObGxfdkZFRFlsQjVUcXJqWUNwX2t2MDk2c2htU1NJTU90UXFGaEVKeWhrSTJGSXNDZmpsYy1lUVdWbEp0QzhGZTdMRFExNDViaWNkbkVERThoZ3otYzdZLThlVVh3cXo2Q1luLW9zNA?oc=5","date":"2025-11-04","type":"pipeline","source":"moomoo.com","summary":"Baiyang Medicine Deepens Cooperation with CSL Behring; Minimum Procurement Volume of Human Albumin in the First Three Years Will Be No Less Than 15 Million Bottles | Flash Report - moomoo.com","headline":"Baiyang Medicine Deepens Cooperation with CSL Behring; Minimum Procurement Volume of Human Albumin in the First Three Ye","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswJBVV95cUxPMGZXNUV6NkdpTFRMZjhpMFlFbkNlSHE3SW1lemtqeVpHUTFZSGEzZzlpb1ZCUHowMlBNbEJZMmlWTUhfZnV6LXdBRktGX2o1TnBzclUwLTdMWUxuMndmSThrWWlCUVlXaFpUZHpyNHoyby1pUXgzcGFsWWxHVVJETk9pOEctODlHUXVkUlBQY2NOUzZ6cTdON01ZRFVla1hpcnlEUmdrdUt3RFhCcXFwT3cxTEd1bEZpd2xTMmpnUWRtVjQwUEpQeUZoSGY5T05lMWtMelptQWlnSzBGZkt5Uk8tcXpUeG93TzRYMXF6OXUxem1feWIwNHBZakNUQjNrQnBERzVMNDJUX04zZ2RiVDh3UEJ3YUhiVWJsQktfM1NYMk1UTGF3bHY2cXpQc3YzbElV?oc=5","date":"2025-10-27","type":"pipeline","source":"PR Newswire","summary":"ISPE Names CSL Behring the 2025 ISPE Facility of the Year Awards (FOYA) Overall Winner for its Project Aurora Plasma Base Fractionation Facility (Facility F) - PR Newswire","headline":"ISPE Names CSL Behring the 2025 ISPE Facility of the Year Awards (FOYA) Overall Winner for its Project Aurora Plasma Bas","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxORjczd2dNbXI5clBHQlBlSEFmWldBSk54NXFsSnUyUjlaa1RLd2xPajFpRi1tOURVQllJTVQtSGhDemNReEFmSkt6MDBoUVNUbVROb0FjNDN3WE4wSERHNHZqaHhmd2hCdXU2UW9ReG9JVUllM1VERDliQWVmQTJrSjF0cGFBMTFXWndUSDVvR0IzRWU3dHJqZWNNYm9aSUxibWdLWDRHanY5QQ?oc=5","date":"2025-09-02","type":"pipeline","source":"Bioprocess Online","summary":"CSL Behring's Robotics Push Is One Of The Biggest We've Seen Yet - Bioprocess Online","headline":"CSL Behring's Robotics Push Is One Of The Biggest We've Seen Yet","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxPWTJQRDN0dXh1NERWd3JtaVBFMHVKQy1TcjkzM09yMk15UmRsY2hYX3BqRHRrLXM5bTAzOUExNHFaZUtVZTBabUlyVl9hd3VsX2NlalhtNzhGbk9MRkNrOXdVc1pfOFpaTU9xOTlaNVpfT05kREZYNGZKSVpTNGlWcHBaM0hmbjA?oc=5","date":"2025-08-20","type":"pipeline","source":"pharmaphorum","summary":"CSL will slash headcount and hive off vaccine business - pharmaphorum","headline":"CSL will slash headcount and hive off vaccine business","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxNSE8ycW96YzJJRThOYXNvc1RmekU5WUw1YmFtanVvdWlWdk5QRnRsakEzUlFMaWlyMVY1VGR2YXAwS0FPMkNwQndZcC1hUUtoWVFDcXZZYl9ia3BjbEtyNy01dUZRMktPVzJMQlVSNG5POVE2d29mWDFRU0NsY1R3WGY3NHJlZHEtZUJFQ0IzOWhhQlhMeDhxWl84VnJmZw?oc=5","date":"2025-08-19","type":"pipeline","source":"Fierce Biotech","summary":"CSL to lay off up to 15% of workforce, cut R&D costs and spin out vaccine unit - Fierce Biotech","headline":"CSL to lay off up to 15% of workforce, cut R&D costs and spin out vaccine unit","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxQdS1nVG9ndVJRSDNHQ3N3ZV9GUUpsNTBvTnNtZHc0T2hqcTM4bFUxdGFQcVVXc3ljbnZialVRZVpjWWdwdF82MkVBZnIzOUJzMXNaZ1EwU2ZGbTBFbjYtYlBZNG9HX1pFRS1GMGZhaVYzejlWQjdzNnNrRHJVZ1ZaUWI3RnVQY2hRcUNvTWdoY21kX0RISjlVWDdLcGRmemo3NmZlUEkxc2x5RG5VUFVXYnUtYkVtQW02cmFWQXdRZ0owUWdSLS12YUhR?oc=5","date":"2025-07-16","type":"pipeline","source":"Global Biotechnology Company","summary":"CSL’s Plasma Fractionation Facility Wins Pharmaceutical Engineering Award - Global Biotechnology Company","headline":"CSL’s Plasma Fractionation Facility Wins Pharmaceutical Engineering Award","sentiment":"neutral"}],"patents":[],"drugCount":36,"phaseCounts":{"phase_2":6,"marketed":15,"phase_3":12,"discontinued":1,"phase_1":2},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}